Stay updated with breaking news from Exa Cel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Food and Drug Administration is expected to approve a new gene editing therapy for sickle cell disease, its first green light for a Crispr treatment.
Casgevy, made by two Boston-based pharmaceutical companies, is the first gene therapy based on a technology sometimes called "genetic scissors."
The Food and Drug Administration approved a new gene editing therapy for sickle cell disease, its first green light for a Crispr treatment.
New FDA-approved therapy treatments that use genetic modification called CRISPR may lead to a sickle cell disease cure.
The FDA's approval of Casgevy, which uses the Nobel Prize-winning gene-editing therapy to treat patients with sicke cell disease, opens the door to many other therapies.